About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA). For additional information, please see the “About Access to Information Requests” webpage.
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 10 record(s)
Nothing to report this month
Organization: Patented Medicine Prices Review Board Canada
Nothing to report this month
Organization: Patented Medicine Prices Review Board Canada
Req # A-2021-07238
Copies of all information, data, document, or correspondence concerning the PMPRB's classification of the following drug products: NOVORAPID and FIASP, each a product of NOVO NORDISK CANADA INC, a corporation located at 101-2476 Argentia Road, Mississauga, Ontario, Canada L5N 6M1, including but not limited to classifications based on drug product line extensions, similar chemical entities, comparable dosages, or a reasonable relationship between the two drugs, as well as any other analysis, comments, or information related to the classification of these two drugs.Organization: Patented Medicine Prices Review Board Canada
May 2021
Req # A-2021-07885
Copies of all briefing notes provided to the Deputy Minister regarding the implementation of the new PMPRB guidelines on July 1, 2021 from January 1, 2021 to April 28, 2021.Organization: Patented Medicine Prices Review Board Canada
May 2021
Req # A-2021-07888
Copies of all briefing notes provided to the Deputy Minister regarding the possible delay in the implementation of the new PMPRB guidelines from January 1, 2021 to April 28, 2021.Organization: Patented Medicine Prices Review Board Canada
May 2021
Req # A-2021-07890
Copies of all emails sent/received from Douglas Clark, Tanya Potashnik, Mitchell Levine and Isabel Jaen Raasch discussing the possible delaying in the implementation of the new PMPRB guidelines from January 1, 2021 to April 28, 2021.Organization: Patented Medicine Prices Review Board Canada
May 2021
Req # A-2021-07891
Copies of all emails and meeting summaries regarding the PMPRB's consultation with IMC about the new PMPRB guidelines.Organization: Patented Medicine Prices Review Board Canada
May 2021
Req # A-2021-07893
Copies of emails, HR work plans, and other documents among PMPRB executives regarding the increase in hiring of PMPRB employees from June 1, 2019 to April 28, 2021.Organization: Patented Medicine Prices Review Board Canada
May 2021
Req # A-2021-09406
Copies of emails to/from/cc'ing Douglas Clark, Tanya Potashnik and Mitchell Levine on negative feedback from groups consulted over the new PMPRB guidelines from June 1, 2019 to December 31, 2020.Organization: Patented Medicine Prices Review Board Canada
May 2021
Req # A-2021-09407
Copies of emails to/from/cc'ing Douglas Clark, Tanya Potashnik and Mitchell Levine on negative feedback from the public over the new PMPRB guidelines from June 1, 2019 to December 31, 2020.Organization: Patented Medicine Prices Review Board Canada
May 2021